Skip to main content
Back
AMLX logo

Amylyx Pharmaceuticals, Inc.

Data quality: 100%
AMLX
NASDAQ Healthcare Biotechnology
$13.53
▼ $0.28 (-2.03%)
Mkt Cap: 1.12B
Day Range
$13.52 $14.43
52-Week Range
$3.11 $17.49
Volume
875,132
50D / 200D Avg
$14.34 / $11.68
Prev Close
$13.81

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -7.8 0.4
P/B 3.7 2.9
ROE % -61.6 3.7
Net Margin % 3.8
Rev Growth 5Y % 10.0
D/E 0.0 0.2

Key Takeaways

Debt/Equity of 0.02 — conservative balance sheet
Negative free cash flow of -123.48M
PEG of 0.12 suggests growth is underpriced

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-61.59%
ROIC-36.94%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
0.02
Current Ratio14.27
Interest Coverage0.00

Valuation

P/E Ratio
-7.77
P/B Ratio3.68
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -100.00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -144.74M
ROE -61.59% ROA -43.51%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -123.48M
ROIC -36.94% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.02 Current Ratio 14.27
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -7.77 P/B Ratio 3.68
P/S Ratio N/A PEG Ratio 0.12
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.12B Enterprise Value 903.99M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 87.37M 380.79M 22.23M 0.0
Net Income -144.74M -301.74M 49.27M -198.38M -87.93M
EPS (Diluted) -1.53 -4.43 0.70 -2.98 -1.52
Gross Profit -525,000.0 45.22M 355.35M 19.24M 0.0
Operating Income -153.29M -314.73M 38.80M -201.34M -82.69M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 332.65M 193.63M 517.45M 391.45M 105.61M
Total Liabilities 27.39M 28.87M 84.02M 50.85M 256.78M
Shareholders' Equity 305.26M 164.77M 433.43M 340.61M -151.17M
Total Debt 5.96M 1.98M 4.24M 6.28M 0.0
Cash & Equivalents 226.65M 77.39M 170.20M 62.53M 50.19M
Current Assets 323.67M 189.43M 464.67M 382.13M 104.95M
Current Liabilities 22.69M 28.41M 82.04M 46.61M 17.40M